Single nucleotide polymorphisms (SNPs) in the OPRM1 gene have been associated with vulnerability to opioid dependence. The current study identifies an association of an intronic SNP (rs9479757) with the severity of heroin addiction among Han-Chinese male heroin addicts. Individual SNP analysis and haplotype-based analysis with additional SNPs in the OPRM1 locus showed that mild heroin addiction was associated with the AG genotype, whereas severe heroin addiction was associated with the GG genotype. In vitro studies such as electrophoretic mobility shift assay, minigene, siRNA, and antisense morpholino oligonucleotide studies have identified heterogeneous nuclear ribonucleoprotein H (hnRNPH) as the major binding partner for the G-containing SNP site. The G-to-A transition weakens hnRNPH binding and facilitates exon 2 skipping, leading to altered expressions of OPRM1 splice-variant mRNAs and hMOR-1 proteins. Similar changes in splicing and hMOR-1 proteins were observed in human postmortem prefrontal cortex with the AG genotype of this SNP when compared with the GG genotype. Interestingly, the altered splicing led to an increase in hMOR-1 protein levels despite decreased hMOR-1 mRNA levels, which is likely contributed by a concurrent increase in single transmembrane domain variants that have a chaperone-like function on MOR-1 protein stability. Our studies delineate the role of this SNP as a modifier of OPRM1 alternative splicing via hnRNPH interactions, and suggest a functional link between an SNP-containing splicing modifier and the severity of heroin addiction.
Introduction
The opioid receptor gene OPRM1 undergoes extensive alternative pre-mRNA splicing, creating an array of splice variants that are conserved from rodent to human. These splice variants can be categorized into the following three major types based on receptor structure: (1) full-length C-terminal variants with 7-transmembrane (TM) domains; (2) truncated variants containing 6-TM domains; and (3) truncated variants containing a single TM (Fig. 1) . Increasing evidence suggests that these splice variants play important roles in mediating the complex actions of various opioids (Pan, 2005; .
Serving as the primary target for most clinical opioids, the OPRM1 gene has been considered as the predominant genetic candidate responsible for vulnerability to opioid dependence (Bond et al., 1998; Uhl et al., 1999; Hoehe et al., 2000; Luo et al., 2003; Ikeda et al., 2005; , as well as dependence on other substances of abuse, such as alcohol and nicotine (Kim et al., 2004; Lerman et al., 2004; Ray and Hutchison, 2004; Berrettini and Lerman, 2005; Zhang et al., 2006a) . Of the 4536 single nucleotide polymorphisms (SNPs) in the human OPRM1 gene identified in the dbSNP database, rs1799971 (A118G) has been the most extensively studied in association with dependence and addiction to drugs of abuse, such as heroin.
An SNP located in intron 2 (rs9479757 or IVS2 ϩ 31A/G) was initially reported to be associated with heroin consumption in a Han-Chinese population (Shi et al., 2002) . In a twin population, this SNP was also associated with smoking initiation and nicotine dependence (Zhang et al., 2006b ). Additionally, rs9479757 was found to be associated with pressure pain sensitivity in healthy Han-Chinese women (Huang et al., 2008) , and with the severity of HIV infection as well as the response to HIV treatment (Proudnikov et al., 2012) .
Studies have suggested the functional significance of several OPRM1 SNPs. For example, A118G increases the affinity of MOR-1 for ␤-endorphin (Bond et al., 1998; Kroslak et al., 2007) , and lowers expression of MOR-1 mRNA and protein likely via altering an mRNA secondary structure , or reducing the N-glycosylation and protein stability of MOR-1 (Huang et al., 2012) . The roles of OPRM1 SNPs have also been implicated in modulating agonist-induced receptor signaling and promoter activities (Befort et al., 2001; Kraus et al., 2001; Wang et al., 2001; Bayerer et al., 2007; Ravindranathan et al., 2009; Fortin et al., 2010) . However, little is known about the effect of SNPs on OPRM1 alternative splicing.
In the current study, we identify an association of SNP rs9479757 with heroin addiction severity among Han-Chinese male heroin addicts, and explore the role of this SNP on OPRM1 alternative splicing. Our data suggest that the G-containing SNP site functions as an intronic splicing enhancer (ISE) that mainly binds heterogeneous nuclear ribonucleoprotein H (hnRNPH), and that a G-to-A transition of the SNP weakens ISE via reducing hnRNPH binding. Consequently, weakened ISE-hnRNPH binding promotes exon 2 skipping, leading to altered expressions of OPRM1 splice-variant mRNAs and hMOR-1 proteins. We also provide data on potential mechanisms by which hnRNPH regulates alternative splicing through the SNP-containing ISE. , Gly-ol-enkephalin (DAMGO)] were obtained from PerkinElmer. All oligodeoxynucleotides (oligos) used in bacterial artificial chromosome (BAC) minigene constructs and PCRs and RNA oligos were synthesized by Sigma-Aldrich and Integrated DNA Technologies, respectively. Ambion Silencer Select siRNAs were obtained from Life Technologies. Vivo-morpholino oligos were synthesized by Gene Tools. Be(2)C cells were obtained from American Type Culture Collection. The rabbit anti-hnRNPH antibody was a gift from Dr. Douglas Black (University of California, Los Angeles, Los Angeles, CA). The goat anti-hnRNPH (N-16), anti-hnRNPF (N-15), anti-hnRNPA1 (E-17), anti-hnRNP A2/B1 (E-2), anti-hnRNPU (C-15), anti-hMOR-1 exon 4 (C-20), anti-actin (I-19), and anti-GAPDH (6C5) antibodies were obtained from Santa Cruz Biotechnology. All other materials were obtained from the sources listed.
Materials and Methods

Materials
Study subjects. A total of 332 male heroin addicts (case group) were recruited from Ningbo city through the Ningbo Addiction Research and Treatment Center of Zhejiang Province, People's Republic of China, based on Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for substance abuse and dependence. We did not include female subjects in this study because there were fewer female heroin addicts in the Ningbo city area. All subjects were males of HanChinese origin with a mean age of 31.8 Ϯ 7.5 years, and had no serious psychiatric symptoms, or a history of hematological diseases, or severe impairment of the liver or kidneys. A total of 190 healthy individuals (control group) were recruited from among voluntary blood donors in the Ningbo blood center of Zhejiang Province. All subjects were males of HanChinese origin and had no history of drug abuse or mental illness. There was no significant difference in age between the case group (31.8 Ϯ 7.5 years) and the control group (30.7 Ϯ 8.4 years). The study protocol was approved by the Ethics Committee of Ningbo Addiction Research and Treatment Center, and written informed consent was obtained from all subjects.
Classification of heroin addiction severity. Heroin addicts were classified into three groups (mild, moderate, and severe) using standard criteria previously described for heroin addiction severity (Xie et al., 2013) , and performed through a questionnaire that collected information including age, education, employment, marriage, and specific information related to heroin abuse, such as drug route, duration, and daily selfadministrated dosage. Addicts who smoked Ͻ0.5 g/d heroin for Ͻ1 year were classified into the mild group, while addicts who smoked Ͼ1.5 g/d of heroin for Ͼ2 years or injected Ͼ0.5 g of heroin for Ͼ6 months were grouped into the severe group. The remaining addicts were placed into the moderate group. There was no significant difference in age among the mild (31.2 Ϯ 6.8 years), moderate (31.7 Ϯ 7.8 years), and severe (32.1 Ϯ 7.3 years) groups.
TaqMan SNP genotyping. Genomic DNA was extracted from leukocytes of all blood samples provided using the standard phenolchloroform method. rs9479757 in case and control subjects was genotyped using TaqMan SNP assay (Applied Biosystems) according to the manufacturer's protocol. Genotype calls were determined using Allelic Discrimination software (Applied Biosystems). Five percent of the samples were duplicated to verify the accuracy rate of genotyping. Any deviation from the Hardy-Weinberg equilibrium and the association between genotype/allele frequencies and phenotype were determined using a Pearson 2 test (chisq.test, R version 3.0.2). Tag SNP selection, Sequenom MassARRAY genotyping. To identify an optimal set of tagging SNPs for the OPRM1 region, we extracted all SNPs in a ϳ105 kb OPRM1 region (chromosome 6: 154359443-154464655, build 37) with minor allele frequency of Ͼ5% in individuals of Asian ancestry, using data from the 1000 Genomes Project. Using a greedy algorithm, we identified 30 SNPs that maximally captured all common variants in the region with pairwise tagging r 2 Ͼ 0.8. Genotyping was performed by Shanghai Benegene Biotechnology Co., Ltd. using the Sequenom MassARRAY system (Sequenom Inc.), a chip-based assay using mass spectrometry. Seven of the 30 SNPs were excluded due to sequence-based complexity. Twenty-three SNPs, including rs9479757 and rs1799971, were genotyped in all samples from the 332 heroin addicts in the case group. SpectroTYPER software (Sequenome Inc.) was used to analyze the data. Associations among the three categorical phenotypes and each SNP were analyzed using the Pearson 2 test (chisq.test, R version 3.0.2). Postmortem samples. Fresh frozen human postmortem prefrontal cortex (PFC) samples were obtained from a postmortem collection of Caucasian Swedish and Hungarian subjects processed under conditions that have been previously described (Drakenberg et al., 2006; Jacobs et al., 2013) . Briefly, these subjects were recruited at the National Institute of Forensic Medicine, Karolinska Institute, Stockholm, Sweden, as well as from the Department of Forensic Medicine at Semmelweis University (Budapest, Hungary) under guidelines approved by the local ethics committees. Tissue punches from 27 male subjects with a mean age 27.5 Ϯ 7.2 years who died from myocardial infarction and had negative toxicology results for psychoactive substances or a history of psychiatric illness were used for RNA and protein extraction.
In vitro transcription coupled translation and purification HIS-tagged hnRNPH. An (HIS) 6 -GGGS tag was fused into the N terminus of hnRNPH in pCMV6-XL4 (OriGene) by using Change-IT Mutagenesis Kit (Affymetrix). The resulting plasmid was used as template to make (HIS) 6 -tagged hnRNPH protein by a T7 transcription/translation coupled (TnT) system (Promega) according to the manufacturer's protocol. (HIS) 6 -tagged hnRNPH was purified by using the MagZ system (Promega). Briefly, 375 l of TnT mixture transcribed/translated from 7.5 g of plasmid were incubated with 420 l of MagZ Binding Particles in Mag-Binding/Washing buffer (Mag-B/W buffer, 20 mM sodium phosphate, pH 7.4, 500 mM NaCl, 0.3% Triton X-100) at room temperature for 30 min. After washing four times with Mag-B/W buffer containing 10 mM imidazole, bound proteins were eluted with 1 M imidazole, pH 7.5, and used in an electrophoretic mobility shift assay (EMSA).
Electrophoretic mobility shift assays. EMSA was performed as described previously (Lefave et al., 2011) . Briefly, a 32 P-labeled 26 mer RNA oligo (86 fmol) containing the G allele (G31, 5Ј-GCC UGA GGG AAG GAG GGU UCA CAG CC-3Ј) was incubated with 10 g of nuclear extract (NE) isolated from Be(2)C cells as previously described (Pan, 2002) or HIS-tagged hnRNPH with or without unlabeled RNA oligo in binding buffer [20 mM HEPES-KOH, pH 7.9, 100 mM KCl, 3.2 mM MgOAc, 20 mM creatine phosphate, 1.3 mM ATP, 12% glycerol, 1 mM DTT, amd 10 g of poly(rA)] at 30°C for 18 min. For supershifting assay, an hnRNPH antibody (a gift from Dr. Douglas Black, University of California, Los Angeles) or a rabbit IgG control (Santa Cruz Biotechnology) was first incubated with nuclear extract at 30°C for 8 min before adding the probe. The reaction mixture was then separated on a 4% acrylamide gel in 0.5 ϫ TBE buffer (45 mM Tris base, 45 mM boric acid, 1 mM EDTA) containing 2.5% glycerol. The gel was exposed on film (BioMax MS, Kodak) at Ϫ80°C. For competition assay, ϳ86 fmol 32 P-labeled G31 was incubated with 10 g of Be(2)C NE in the absence or presence of unlabeled RNA oligos at various concentrations from 4.4 to 709 nM. Bands on film were imaged with ChemiDoc MP System (Bio-Rad) and quantified with ImageLab 4.0 (Bio-Rad). The data were analyzed by nonlinear regression (Prism 5.0) to obtain IC 50 values.
UV cross-linking. A 26 mer RNA oligo with the G allele or the A allele of rs9479757 was covalently linked with biotin-triethylene glycol (a triethylene glycol spacer) at the 5Ј site during synthesis (Integrated DNA Technology). The 500 pmol biotinylated RNA oligo were bound to 250 l of streptavidin-coupled magnetic beads (M280-streptavidin, Life Technologies) in Binding & Washing (B&W) buffer (5 mM Tris/HCl, pH 7.5, 0.5 mM EDTA, and 1 M NaCl) following the manufacturer's protocol. RNA oligo-bound beads were incubated with 2.6 mg of NE from Be(2)C cells in binding buffer (see EMSA) at 30°C for 26 min and then at 4°C for 30 min. The mixture was transferred into one well in a six-well plate, and was UV cross-linked at 254 nm for 18 min in Stratagene UV Stratalinker 2400 (Agilent). After washing four times with B&W buffer containing 0.3% SDS, the mixture was digested with 25 g of RNase A (Affymetrix) and 400 U Ambion RNase I (Life Technologies) at 37°C for 30 min. The digested mixture was separated in 4 -20% gradient SDS-PAGE and transferred onto PVDF membranes for Western blot analysis.
Western blot analysis. Samples from the UV cross-linking study and proteins from Be(2)C cells and the PFC tissues were separated in 4 -20% gradient SDS-PAGE and transferred onto PVDF membranes. The PVDF membranes were blocked in a blocking solution containing TBST buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween 20), 4% nonfat dried milk, and 1% BSA at room temperature for 1 h, and incubated with an anti-hnRNPH antibody (1:1000 dilution), anti-hnRNPA1 antibody (1:200 dilution), anti-hnRNPA2/B1 antibody (1:200 dilution), anti-hnRNPU antibody (1:200 dilution), or anti-hnRNPC antibody (1: 200 dilution) and anti-hnRNPF antibody (1:1000 dilution), antihMOR-1 exon 4 antibody (1:1000), anti-actin antibody (1:3000), and anti-GAPDH antibody (1:3000) in the blocking solution at 4°C overnight. After washing with TBST buffer, the membrane was incubated with appropriate peroxidase-conjugated secondary antibodies in TBST buffer at room temperature for 1 h. After washing with TBST buffer, signals were detected by using ChemiGrow reagents (ProteinSimple), imaged with ChemiDoc MP, and quantified using ImageLab 4.0.
BAC minigene constructs, cell culture, and transfection. A human BAC clone (CH17-143P18) covering an ϳ207 kb OPRM1 region from 23 kb upstream of exon 1 to 95 kb downstream of exon 4 was obtained from BACPAC Resources, and used as a template for making BAC minigene constructs with Recombineering System obtained from the National Cancer Institute Biological Resources Branch (Lee et al., 2001 ) and a modified positive/negative (Rpsl-kanmycin) selection system (Wang et al., 2009) following the described procedures. Briefly, CH17-143P18 was first transformed into the SW105 strain by electroporation. All recombineering procedures were performed in the SW105 transformats. The original CH17-143P18 clone contained the G allele at positions 24, 25, 29, 31, and 32 of intron 2. To make BAC clones with the A allele at these positions, we inserted the rpsl-kana cassette at these desired positions through a positive kanamycin selection. The rpsl-kana cassette flanking ϳ50 bp of the designated sequences for homologous recombination was generated by PCR, and electroporated into the competent SW105-CH17-143P18 cells in which a recombinase was induced by incubating the cells at 42°C for 15 min. Positive clones were selected on LB plates containing 20 g/ml kanamycin and 12 g/ml chloramphenicol, and verified by PCR with appropriate primers. In a negative selection, a fragment containing the A allele was electroporated into induced positive cells with the rpsl-kana cassette and selected on LB plates containing 12 g/ml chloramphenicol and 1 mg/ml streptomycin for replacing the rpsl-kana cassette. The final BAC constructs with a single A mutation were confirmed by DNA sequencing. All electroporations were performed using a 0.1 cm cuvette and Gene Pulser II (1.75 kV, 25 F, and 200 ⍀; Bio-Rad). The integrity and accuracy of the BAC constructs in each step were verified by digestion patterns with several restriction enzymes. We inserted a tdTomato/pgk-neo/CMV cassette upstream of the exon 1 using positive selection. tdTomato (Clontech) was used for monitoring transfection efficiency, and pgk-neo was used for selection. The CMV promoter from pcDNA3 (Life Technologies) is used for the following two purposes: (1) to drive expression of OPRM1 variant mRNAs since the exon 1 promoter activity in the BAC constructs was very low; and (2) to provide unique sequences for the design of a sense primer in PCR to detect expressions of the OPRM1 variants only from the BAC constructs so that expressions of the endogenously expressed OPRM1 variants in Be(2)C cells can be excluded.
Be(2)C cells were maintained in MEM plus NEAA:F12 medium containing 10% fetal calf serum at 37°C in a 5% CO 2 /95% air-humidified atmosphere. BAC DNA transfection was optimized using NeuroMag reagent (OZ Biosciences). Briefly, 4 g of BAC DNA purified by Maxiprep (Qiagen) was incubated with 14 l of NeuroMag reagent at room temperature for 20 min. The mixture was then added into cells (on a 12-well plate) for incubating at 37°C for 20 min under a magnetic plate. We usually obtain ϳ50 -70% transfection efficiency determined by tdTomato fluorescence under microscopy. Cells were harvested after 48 h of transfection for RNA and protein extraction.
RNA isolation, RT-PCR, and RT-SYBR green quantitative PCR (qRT-PCR) . Total RNA was extracted from cells and brain tissues using miRNeasy Kit (Qiagen) according to the manufacturer's protocol. Five micrograms of total RNA were treated with Turbo DNase I (Life Technologies) and reverse transcribed with 0.8 g of random hexamer (GE Life Sciences) and 200 U of Superscript III reverse transcriptase (Life Technologies) according to the manufacturer's protocols. The firststrand cDNA was then used as a template in regular PCR or quantitative PCR (qPCR). Regular PCR was performed using Platinum TaqDNA polymerase (Life Technologies) to amplify exogenous (transfected BAC minigene constructs) hMOR-1, hMOR-1S, and hMOR-1Z with SP-1 (5Ј-GGC TAC CCA TAC GAC GTG CCA G-3Ј) and AP-1 (5Ј-GCT TGG TGA AGG TCG GAA TGG CAT G-3Ј) primers, and endogenous hMOR-1, hMOR-1S, and hMOR-1Z with SP-2 (5Ј-GGT GCT CCT GGC TAC CTC GCA C-3Ј) and AP-1 primers, as well as human glyceraldehyde 3-phosphate dehydrogenase (hG3PDH) with SP-3 (5Ј-ACC ACA GTC CAT GCC ATCC AC-3Ј) and AP-2 (5Ј-TCC ACC ACC CTG TTG CTG TA-3Ј) primers for loading control. PCR products were analyzed on 1.5% agarose gel, stained with ethidium bromide, and imaged using the ChemiDoc MP system. qPCR was performed using HotStart SYBR Green Master Mix (Affymetrix) as previously described . A sense primer, SP-1, and three antisense primers, AP-3 (5Ј-CTT CAT CTT GGT GTA TCT GAC AAT CAC ATA C-3Ј), AP-4 (5Ј-CTT CCA GAT TTT CTA GCT GAC AAT CAC ATA C-3Ј), and AP-5 (5Ј-GTG TAC AAT CTA TGG AAC CTG ACA ATC ACA TAC-3Ј), were used for amplifying exogenous hE1-2 (exons 1-2 for hMOR-1), hMOR-1S, and hMOR-1Z, respectively. The SP-2 and AP-3, AP-4, and AP-5 primers were used for amplifying endogenous hE1-2, hMOR-1S, and hMOR-1Z, respectively. qPCRs for three reference genes including human succinate dehydrogenase subunit A (hSDHA) using SP-4 (5Ј-TGC CTG TGA CAA CGT AGA GC-3Ј) and AP-6 (5Ј-CCG CAG GAT AGT TAG GCT GAA-3Ј), human ␤-2 microglobulin (hB2M) using SP-5 (5Ј-ACA GCA GTG TCA ACG TAG TAG T-3Ј), and AP-7 (5Ј-CGG CAG GCA TAC TCA TCT TTT T-3Ј) and hG3PDH using SP-3 and AP-2 were used for determining normalization factor (NF) using the following formula, which was described previously (Pfaffl et al., 2004) 
1/3 . All variant C(t) values were normalized with the NFs to obtain ⌬C(t): (⌬C(t) ϭ C(t) variant Ϫ NF). Fold change was calculated through the 2 Ϫ⌬⌬C(t) format, where ⌬⌬C(t) value was the difference in the ⌬C(t) values between a variant and a reference.
siRNA and vivo-morpholino antisense oligo treatment. Different concentrations of a Silencer Select siRNA targeting hnRNPH1 (si-H1; 5Ј-GAA GCA UAC UGG UCC AAA Utt-3Ј; Ambion, Life Technologies) were transfected, either alone or combined with a BAC minigene construct, into Be(2)C cells in a 24-well plate using NeuroMag reagent (see above). A Ambion Silencer Select negative control siRNA (Life Technologies) was used as a control (si-Ctr). After 48 h of transfection, cells were harvested for protein and RNA extraction. Proteins from whole cells were extracted by directly adding SDS-PAGE loading buffer into wells containing the cells. After heating at 100°C for 10 min and centrifugation at 15,000 ϫ g for 10 min, the supernatants were separated on 4 -20% SDS-PAGE gels and transferred onto PVDF membranes for Western blot analysis. For antisense vivo-morpholino studies, Be(2)C cells were treated with 1 M 25mer antisense vivo-morpholino oligo targeting the region containing rs9479757 (antisense: 5Ј-CAG GCT GTG AAC CCT CCT TCC CTC A-3Ј) in culture medium for 48 h. A 25mer control vivo-morpholino oligo [control: 5Ј-CAG CCT CTG AAG CCT CGT TGC CTC A-3Ј, in which five bases (shown in italics) in the antisense oligo were switched] was used as a control. RNA from siRNA-and vivomorpholino-treated cells was extracted as described above.
Receptor binding assay. Membrane were isolated from Be(2)C cells and [ 3 H]DAMGO binding as previously described (Pan et al., 1999 (Pan et al., , 2005 . [ 3 H]DAMGO binding was performed at 25°C for 60 min in 50 mM potassium phosphate buffer, pH 7.4, containing 5 mM magnesium sulfate. Specific binding was determined as the difference between total binding and nonspecific binding, defined by levallorphan (1 M). Protein concentration was determined by Lowry method using BSA as the standard.
[ 35 S]GTP␥S binding assay. [ 35 S]GTP␥S binding assay was performed as described previously (Bolan et al., 2004; Pasternak et al., 2004) . Briefly, membranes prepared from Be(2)C cells were incubated in the presence and absence of 1 M DAMGO for 60 min at 30°C in the assay buffer (50 mM Tris-HCl, pH 7.7, 3 mM MgCl 2 , 0.2 mM EGTA, 10 mM NaCl) containing 0.05 nM [
35 S]GTP␥S (PerkinElmer) and 60 M GDP. The percentage of stimulation was determined by dividing the counts from membrane treated with the DAMGO by those from membrane that had not been treated and multiplying 100.
RNA affinity purification and liquid chromatography-tandem mass spectrometry. Five hundred picomoles biotinylated RNA oligos (the same as used in the UV cross-linking studies) were bound to 75 l of Monomeric Avidin UltraLink Resin (Pierce) following the manufacturer's procedures. The RNA oligo-bound resin was then incubated with 1.8 mg of nuclear extract from Be(2)C cells that was precleared with resin in bind- ing buffer (see EMSA) at 30°C for 26 min and then at 4°C for 30 min. After washing two times with binding buffer, bound proteins were eluted with elution buffer (0.1 M sodium phosphate, 0.15 M NaCl, pH 7.0, 2 mM biotin). The elute was concentrated using an Amicon Ultra concentrator (0.5 ml, 3 kilodaltons; Millipore) and was loaded onto a 10% SDS-PAGE gel and electrophoresed into a 4 mm separation gel. After staining with Coomassie blue, the protein-dense band was cut and digested with trypsin, and was batch purified on reversed-phase micro-tips, and the resulting peptide mixtures were then analyzed by LC-Packings/Dionex Ultimate capillary-HPLC coupled to an Applied Biosystems/MDS Sciex Q-STAR tandem mass spectrometry (MS/MS) system. MS/MS data were then taken for searching a "nonredundant" protein database (3,245,378 entries; National Center for Biotechnology Information) using the MASCOT MS/MS ion search program (Perkins et al., 1999) . Scaffold 4.0.5 (Proteome Software) was used to further validate and crosstabulate the MS/MS-based peptide and protein identifications. Protein and peptide probability was set at 95% with a minimum peptide requirement of 1. Protein-protein interactions among identified proteins were obtained from Ingenuity databases (Ingenuity Systems). Statistical analysis. Pearson 2 test was performed by using chisq.test, R version 3.0.2 for SNP analysis. The linkage disequilibrium (LD) plot and the haplotype analysis were performed by using Haploview version 4.2. The test of association independent of rs9479757 was performed by using Plink version 1.07. Two-tailed Student's t tests (Prism 5.0) were used in analyzing data from Western blots of the UV cross-linking study, the morpholino oligo study in Be(2) cells and human postmortem PFC samples, and qPCRs from the hnRNPH1 siRNA study, the BAC minigene study in Be(2)C cells treated with morpholino oligos and human postmortem PFC samples, as well as [ 3 H]DAMGO and [ 35 S]GTP␥S binding assays in the morpholino oligo study. One-way ANOVA followed by post hoc Newman-Keuls analyses (Prism 5.0) was used in analyzing data from the competing EMSA study, qPCRs of mutated BAC minigene constructs, and Western blots from the hnRNPH1 siRNA study. Data are represented as the mean Ϯ SEM from at least three independent experiments. Statistical significance was set at p Ͻ 0.05.
Results
rs9479757 is associated with heroin addiction severity in HanChinese male heroin addicts
To investigate whether rs9479757 is associated with heroin addiction, we genotyped 190 normal male healthy subjects (control) and 332 male heroin addicts (case) that were recruited based on DSM-IV criteria. There were a few subjects in the case group who had the AA genotype, and no subjects in the control group with the AA genotype, which is consistent with the low frequency of AA homozygotes in the Asian population (0.8%, from the dbSNP database). The frequencies of AG and GG genotypes in both control and case groups were in Hardy-Weinberg equilibrium. There were no significant differences in either the genotypic or allelic distribution between control and case groups (for genotype: 2 ϭ 1.38, p ϭ 0.501; for allele: 2 ϭ 0.65, p ϭ 0.420; Table  1 ). We then analyzed the association of the genotype and allele frequencies with the severity of heroin addiction, as defined by our standard criteria including route, duration, and self- administrated dosage among the 332 male heroin addicts (Xie et al., 2013) . We found that both genotypic and allelic frequencies showed significant differences among the three heroin addiction groups (for genotype: 2 ϭ 13.79, p ϭ 0.0080; for allele: 2 ϭ 10.47, p ϭ 0.0053; Table 2 ). The AG genotype and the A allele were clearly associated with the mild group, whereas the GG ge- notype and the G allele were predominately associated with the moderate and severe groups. These results suggest that rs9479757 is associated with the severity of heroin addiction.
Haplotype analysis confirms association of rs9479757 with heroin addiction severity To further investigate this genetic association at the OPRM1 locus, we genotyped an additional 22 tag SNPs spanning an ϳ105 kb OPRM1 region among 332 heroin addicts for haplotype analysis. We observed a large amount of LD among many of the SNPs at this region (Fig. 2) . We next asked whether the genotype frequency or allele frequency for each of the SNPs is associated with the three categorical phenotypes of heroin addiction severity. Using a Pearson 2 test on 3 ϫ 3 or 2 ϫ 3 contingency tables, we observed nominally significant associations with three additional SNPs, rs527434 ( p ϭ 0.0109 for genotype), rs632499 ( p ϭ 0.0086 for allele; p ϭ 0.0492 for genotype), and rs13195018 ( p ϭ 0.0365 for allele; p ϭ 0.0320 for genotype), besides rs9479757 (Table 3 ). The observation of additional associations within this haplotype block supports the hypothesis that this genetic variation at OPRM1 is truly associated with heroin addiction severity as opposed to the possibility that the observed association is artifactual due to genotyping errors. Furthermore, the most significant association was with rs9479757 ( p ϭ 0.0053 for allelic test and 0.0080 for genotype test; Table 3 ). As these SNPs are in LD with each other, we further asked whether the haplotype formed by these SNPs is significantly associated with the mild group versus the severe group. In this comparison, the AGCA haplotype was most strongly associated ( p ϭ 0.0088; Table 4 ), but this association was weaker than that observed for rs9479757 in the dichotomous test (mild group vs severe group, p ϭ 0.001) using Haploview software. We also tested each of these three SNPs, rs527434, rs632499, and rs13195018, for an effect on heroin addiction severity (mild group vs severe group) independent of rs9479757. None of the observed effects was independent (Table  5) . In other words, the association signal observed for each of the three other SNPs can be fully explained by their correlation with rs9479757. Together, these data are consistent with the hypothesis that SNP rs9479757 is functionally responsible for the observed association with the severity of heroin addiction.
rs9479757 alters hnRNPH binding in vitro
Generally, the cis-acting elements controlling splicing are located in exons and their adjacent intron regions, although distal intronic cis-elements can also be important. The location of SNP rs949757, 31 bases downstream of exon 2, makes the SNP a favorable candidate for modulating regulatory cis-elements and thus influencing exon 2 splicing. A bioinformatics analysis of available databases for RNA binding protein motifs [Alternative Splicing Database (previously called Alternative Splicing Rainbow); Thanaraj et al., 2004] revealed that the G allele of this SNP corresponds to a high score as a hnRNPH binding site, which has a highly conserved AGGG consensus core sequence ( Fig. 3A ; Caputi and Zahler, 2001) . The G-to-A transition diminished this score, suggesting that SNP rs949757 can alter hnRNPH binding. To test this hypothesis, we performed RNA EMSA with an RNA oligo containing the G allele of the SNP (G31) and nuclear extract from Be(2)C cells, a human neuroblastoma cell line that endogenously expresses the OPRM1 gene. We observed the formation of a major RNA/ protein complex, which was completely abolished by competition with a 50-fold excess of an unlabeled RNA oligo (Fig. 3B) . To investigate whether hnRNPH participated in this RNA/protein complex, we used an hnRNPH antibody in EMSA supershift experiments. The RNA/protein complex was in fact supershifted by the hnRNPH antibody, but not by a control antibody (Fig. 3B) , indicating that hnRNPH is involved in the formation of this complex.
Several other hnRNP proteins such as hnRNPF, hnRNPA1, hnRNPA2/B1, and hnRNPU, as well as SRSF1, can also bind to G triplets or G-rich sequences, and these proteins often interact with each other. The supershifting observed in the EMSA by the hnRNPH antibody only shows that the protein is part of the complex, but does not prove a direct interaction of hnRNPH with the RNA oligo since other polyG-binding proteins could be mediating this interaction. To examine which of these proteins in the nuclear extract from Be(2)C cells is the major binding partner to the RNA oligos containing the SNP, we used UV cross-linking coupled with RNA purification and Western blot analysis, which is a common approach for studying RNA-protein interaction. When the biotinylated G31 oligo was used, it was clear that hnRNPH was efficiently cross-linked, while hnRNPF was not (Fig. 3D) , probably due to its low level in the nuclear extract, as suggested by its absence from the results of the RNA affinity purification coupled to liquid chromatography (LC)-MS/MS experiments, which used the same RNA oligos (see below). Other hnRNP proteins, including hnRNPA1, hnRNPA2/B1, and hnRNPU, as well as SRSF1, also failed to be cross-linked (Fig.  3D) . These results suggest that hnRNPH is indeed the major binding partner for the G31 oligo in the context of the nuclear extract. On the other hand, when the biotinylated A31 oligo was used, the UV cross-linked hnRNPH was greatly diminished (t (4) ϭ 4.26; p Ͻ 0.05; Fig. 3D) , suggesting that the G-to-A transition significantly reduced hnRNPH binding. Similarly, the UV crosslinked hnRNPF was also reduced (t (4) ϭ 5.04; p Ͻ 0.01; Fig. 3D) . A weak UV cross-linking of hnRNPA2/B1 with the A31 oligo, but not the G31 oligo, was detected (t (4) ϭ 9.59; p Ͻ 0.001; Fig. 3D ).
To further confirm that hnRNPH can directly bind to the sequence with the G allele (G31), we purified a (His) 6 -tagged hnRNPH from in vitro TnT. When the purified hnRNPH was used in EMSA, we observed that the purified hnRNPH bound the G31 oligo to form a single complex in a dose-dependent manner (Fig. 3C) . The complex was totally competed with by a 50-fold Haplotypes were constructed with each of the listed SNPs and rs9479757. The likelihood of a null model consisting only of rs9479757 and the alternative model including the other SNP were computed, and a likelihood ratio test was performed. All analyses were done using the chap-independent effect command in Plink version 1.07.
excess of an unlabeled G31 oligo, and completely shifted to a low-molecularweight smear by the hnRNPH antibody, suggesting that hnRNPH can directly bind to the G31 oligo. The different shifting patterns observed when using the hn-RNPH antibody compared with nuclear extract from Be(2)C cells may be due to a conformational change of the hnRNPH by the antibody binding. We next asked whether the A allele can modulate hnRNPH binding in competing EMSA assays. In these assays, RNA/ hnRNPH binding was competed with a series of unlabeled RNA oligos with either a G allele or an A allele at different positions and using varied concentrations of unlabeled oligos (Fig. 4A) . When the unlabeled G31 oligo was used, it competed the complex effectively with IC 50 values of 26 Ϯ 1 nM (Fig.  4B,C) . However, the unlabeled RNA oligo with the A allele (A31) competed the complex poorly with IC 50 values of 89 Ϯ 7 nM, 3.5-fold higher than seen with the G31 oligo (F (5,12) ϭ 6.12; p ϭ 0.0048; post hoc analysis of G31 vs A31, p Ͻ 0.05; Fig. 4B,C) , suggesting that the G-to-A transition of the SNP significantly reduced in vitro binding affinity toward hnRNPH.
As we have shown previously, hn-RNPH binds to a core sequence containing a G triplet (Lefave et al., 2011) . rs9479757 is located at one G triplet. There is another G triplet just five bases upstream of rs949757 (Fig. 4A) . If hn-RNPH is indeed involved in complex formation, mutations in the G positions of both G-triplet sequences should impair hnRNPH binding. We next used four additional mutated RNA oligos with the replacement of A in the indicated positions as A24, A25, A32, and A29 in the competition EMSA. We observed that the A32 oligo that targets the same G triplet as the A31 oligo weakly competed with the complex with IC 50 values of 80 Ϯ 14 nM (post hoc analysis of G31 vs A32, p Ͻ 0.05), which are similar to those of the A31 oligo (Fig. 4 B, C) , suggesting that the G triplet where the SNP is located is important for hnRNPH binding. The A24 or A25 oligo that contained a mutation in the upstream G triplets also showed poor affinities, with IC 50 values of 107 Ϯ 29 and 87 Ϯ 9 nM ( post hoc analysis of G31 vs A24 or A25, p Ͻ 0.05; Fig. 4 B, C) , respectively, further suggesting that the upstream triple G mutations contribute to hnRNPH binding. However, the A29 oligo with a double G mutation just 2 nt upstream of the SNP displayed a similar affinity (IC 50 , 28 Ϯ 4) to that of the G31 oligo ( post hoc analysis of G31 vs A29, p Ͼ 0.05; Fig. 4 B, C) , indi- Exon and intron are indicated by uppercase and lowercase letters, respectively. rs9479757 is shown in red letters. Sequences of RNA oligos used in EMSA are underlined. Potential hnRNPH binding site is shown by a blue line. Extra sequences of mouse and rat are shown in the lower box inserted at relative positions by the vertical lines. B, RNA EMSA. EMSA with 32 P-labeled RNA oligo containing G allele and Be(2)C NE was performed as described in Materials and Methods. Probe, shifted, and supershifted complex bands are indicated by arrows. Competitor (ϫ50) 220 nM unlabeled RNA oligo; H1 antibody was a gift from Dr. Douglas Black (University of California, Los Angeles); control IgG was from Santa Cruz Biotechnology. C, RNA EMSA with purified (HIS) 6 -tagged hnRNPH1 (H1-HIS).(HIS) 6 -taggedhnRNPH1wassynthesizedandpurifiedasdescribedinMaterialsandMethods.Fifteennanograms(1)or30ng(2) of (HIS) 6 -tagged hnRNPH1 were used in EMSA with 32 P-labeled RNA oligo containing the G allele. D, Western blot analysis of UV crosslinking products. Biotinylated G31 or A31 oligo was bound onto strepavidin-magnetic bead, and incubated with Be(2)C nuclear extract. After UV cross-linking, stringent wash, and digestion with RNase A/I, the samples were used in Western blot analysis. Immunoblots with indicated antibodies are shown in the left panel. NE of Be(2)C cells as input controls; G31 and A31, RNA oligos used in UV cross-linking. Quantification of the band intensities on blots measured using ImageLab software (Bio-Rad) is shown in the right panel. All bars are the mean Ϯ SEM. Student's t test was used (n ϭ 3 each). *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001.
cating that only the triple G mutations, and not the double G mutations, have an effect on hnRNPH binding.
rs949757 modulates exons 2/3 skipping/ inclusion of the OPRM1 gene
The position of rs949757 is favorable for its potential role in modulating exon 2 inclusion/skipping. Exon 2 inclusion in exon 1/2/3/4 splicing generates the fulllength 7-TM variant hMOR-1, exon 2 skipping in exon 1/3/4 splicing produces the single TM variant hMOR-1Z, and exon 2/3 skipping in exon 1/4 splicing produces the single TM variant hMOR-1S (Fig. 5) . Although a minigene approach with a regular plasmid is commonly used for studying alternative splicing, it is not optimal in this case since a large portion of the intron has to be excluded due to the size limitation of regular plasmid constructs. We used the BAC minigene constructs containing the complete genomic regions to overcome this problem (Lee et al., 2001) . To investigate the effect of rs949757 on exon 2 inclusion/skipping, we first made two BAC minigene constructs, hBAC-G31 and hBAC-A31, containing identical genomic regions from exon 1 to exon 4 of the human OPRM1 gene, with the exception of either the G or A allele at the rs949757 locus, respectively (Fig. 5A) . When transfected into the Be(2)C cell, the hBAC-G31 construct expressed all three splice-variant mRNAs with the following rank of expression levels: hMOR-1 Ͼ hMOR-1S Ͼ hMOR-1Z (Fig. 5 B, C) . The lower level of hMOR-1Z was probably due to nonsense-mediated decay. The hBAC-A31 construct also produced three splice-variant mRNAs. However, the hBAC-A31 construct generated significantly higher levels of hMOR-1S (F (4,19) ϭ 16.42; p Ͻ 0.0001; post hoc analysis of hBAC-G31 vs hBAC-A31, p Ͻ 0.001) and hMOR-1Z mRNA (F (4,19) ϭ 8.88; p ϭ 0.0003; post hoc analysis of hBAC-G31 vs hBAC-A31, p Ͻ 0.01), and lower levels of hMOR-1 mRNA (F (4,19) ϭ 10.91; p Ͻ 0.0001; post hoc analysis of hBAC-G31 vs hBAC-A31, p Ͻ 0.01), compared with the hBAC-G31 construct (Fig. 5 B, C) . The difference in splicevariant expression levels between the two constructs suggests that the A allele either facilitates exon 2 skipping or impedes exon 2 inclusion. To examine the effect of other adjacent Gs on splicing, we then made three additional minigene constructs, hBAC-A24, hBAC-A29, and hBAC-A32, mutated at positions 24, 29, and 32, respectively. Similar to the hBAC-A31, both hBAC-A24 and hBAC-A32 in- creased exon 2 or exon 2/3 skipping to yield higher levels of hMOR-1S ( post hoc analysis of hBAC-G31 vs hBAC-A24 or hBAC-A32, p Ͻ 0.001) and hMOR-1Z mRNA ( post hoc analysis of hBAC-G31 vs hBAC-A24 or hBAC-A32, p Ͻ 0.01), and lower levels of hMOR-1 mRNA ( post hoc analysis of hBAC-G31 vs hBAC-A24 and hBAC-A32, p Ͻ 0.01 and p Ͻ 0.001, respectively; Fig. 5 B, C) . These findings suggest that both G triplets are necessary for maintaining exon 2 inclusion, and alteration of either one of the G triplets will decrease exon 2 inclusion, most likely by weakening hnRNPH binding. On the other hand, the hBAC-A29 construct showed expression patterns similar to the hBAC-G31 construct ( post hoc analysis of hBAC-G31 vs hBAC-A29, p Ͼ 0.05; Fig. 5 B, C) , which confirmed the in vitro data that the double G mutations were not involved in exon 2 skipping or inclusion. Together, these data suggest that the SNP-contained G-rich region plays an important role in modulating exon 2 inclusion during splicing, likely through its interaction with hnRNPH.
Downregulation of hnRNPH facilitates exon skipping
To further investigate the role of hnRNPH in OPRM1 alternative splicing, we used an siRNA approach to downregulate the expression of hnRNPH protein in Be(2)C cells. Compared with the A single G-to-A mutation in individual BAC minigene constructs is labeled as a red letter in the top box. Splicing of exons 1/2/3/4 is shown by tilted blue line to generate hMOR-1. Splicing exons 1/4 or 1/3/4 is indicated by tilted red or green lines to produce hMOR-1S and hMOR-1Z, respectively. tdTom, tdTomato fluorescent reporter (ClonTech); neo, pGK-neo cassette; CVM, cytomegalovirus immediate early promoter; poly(A), polyadenylation site in exon 4; SP-1 and AP-1, PCR primers used in regular RT-PCR; pBACGK1.1, vector carrying BAC clones. B, Expression of the OPRM1 splice variants from transfected BAC minigene constructs by regular qRT-PCR. RNA was extracted from transfected Be(2)C cells with indicated BAC constructs after 48 h of transfection, and used for regular RT-PCR with SP-1 and AP-1 primers for the variants, and G3PDH primers, as described in Materials and Methods. C, Expression of the OPRM1 splice variants from transfected BAC minigene constructs by qRT-PCR. The same cDNAs in B were used in SYBR green qPCRs, as described in Materials and Methods. hE1-2 mainly represents hMOR-1. The fold change was calculated through the 2 Ϫ⌬⌬C(t) format, where the ⌬⌬C(t) value was the difference of ⌬C(t) values between A mutation constructs and the G31 construct so that the expression level in the G31 construct is always 1. Bars represent the mean Ϯ SEM. One-way ANOVA was used (n ϭ 6 for G31, A31, and A29; n ϭ 3 for A32 and A24). Comparison to the G31 construct: **p Ͻ 0.01; ***p Ͻ 0.001.
si-Ctr, treatment of an si-H1 reduced hnRNPH protein levels in a dose-dependent manner in Be(2)C cells [F (3,8) ϭ 52.03; p Ͻ 0.0001; post hoc analysis: si-Ctr (10 nM) vs si-H1 (10 or 25 nM), p Ͻ 0.001; si-Ctr (25 nM) vs si-H1 (10 or 25 nM), p Ͻ 0.001; si-H1 (10 nM) vs si-H1 (25 nM), p Ͻ 0.05; Fig. 6 A, B] . Downregulation of hnRNPH significantly enhanced the endogenous exon 2 and exons 2/3 skipping to generate higher levels of hMOR-1S and hMOR-1Z, respectively, in Be(2)C cells (for hMOR-1S: t (6) ϭ 3.42, p Ͻ 0.05; for hMOR-1Z: t (4) ϭ 5.83, p Ͻ 0.01; Fig. 6C,D) . Although the hnRNPH siRNA had a tendency to lower expression of the endogenous hE1-2 that mainly represents hMOR-1, this effect was not statistically significant. We also examined the effect of downregulating hnRNPH on exon 2 inclusion/skipping of the transfected BAC minigene construct hBAC-G31 in Be(2)C cells. When hnRNPH was downregulated by the siRNA, we observed that the exogenous hMOR-1S and hMOR-1Z mRNA levels again increased significantly (for hMOR-1S: t (16) ϭ 4.78, p Ͻ 0.001; for hMOR-1Z: t (10) ϭ 3.67, p Ͻ 0.01), while hE1-2 mRNA levels were considerably reduced (t (10) ϭ 3.00, p Ͻ 0.05; Fig.  6C,D) . A similar scenario was seen when the hBAC-A31 and other triple G mutation constructs were used (Fig. 5 B, C) .
It was noticed that the genotype of rs9479757 in the Be(2)C cell line is AG (data not shown). Following treatment with the hnRNPH siRNA, the splicing pattern change in the Be(2)C cells with the heterozygous AG genotype was similar to the splicing pattern change in the exogenously transfected BAC minigene construct (hBAC-G31) with the homozygous GG genotype. Both the splicing changes mimicked those seen in the hBAC-A31 and the other triple G mutation constructs, all of which contain the homozygous AA genotype (Fig. 5 B, C) . These data suggest that the splicing pattern defined by the heterozygous AG genotype in the Be(2)C cells can be further modified toward that defined by Figure 6 . Effect of hnRNPH1 siRNA on exon 2 inclusion/skipping. A, Effect of hnRNPH1 siRNA on the expression of hnRNPH1 protein in Be(2)C cells. An siRNA against hnRNPH1 (si-H1) and control siRNA (si-Ctr; Ambion, Life Technologies) were transfected into Be(2)C cells using NeuroMag reagent as described in Materials and Methods. Lanes 1 and 3: 10 nM siRNA; lanes 2 and 4: 25 nM siRNA. After 48 h of transfection, proteins were extracted from whole cells and used for Western blot analysis with hnRNPH1 or actin antibody, as described in Materials and Methods. B, Quantification of Western blots. Images on the films were analyzed on the ChemiDoc Image System. Band intensities of hnRNPH1 were obtained by adjusting with those of actin, and normalized with that of 10 nM si-Ctr (lane 1). All bars are the mean Ϯ SEM. One-way ANOVA was used (n ϭ 3 each). Red star: compared with lane 1; green star: compared with lane 2; blue star: compared with lane 3. *p Ͻ 0.05; ***p Ͻ 0.001. C, Effect of hnRNPH1 siRNA on exon 2 inclusion/skipping by regular qRT-PCR. RNA extracted from Be(2)C cells transfected with 25 nM of si-Ctr or si-H1 alone (Endogenous), or combined with BAC minigene construct G31 (hBAC-G31) was used in regular RT-PCR with SP-1 and AP-1 primers for the variants and G3PDH primers. Bands for hMOR-1, hMOR-1Z, and hMOR-1S are shown by boxes labeled as 1/2/3/4, 1/3/4, and 1/4, respectively. D, Effect of hnRNPH1 siRNA on exon 2 inclusion/skipping by qRT-PCR. The same cDNAs in C were used in SYBR green qPCR, as described in Materials and Methods. hE1-2 mainly represents hMOR-1. The fold change was calculated through 2 -⌬⌬C(t) format, where the ⌬⌬C(t) value was the difference of ⌬C(t) values between the si-H1 and the si-Ctr samples, so the expression level in the si-Ctr samples is always 1. Bars represent the mean Ϯ SEM. Student's t test was used (for endogenous variants: n ϭ 6 each for hE1-2, n ϭ 4 each for hMOR-1S, and n ϭ 3 each for hMOR-1Z; for exogenous variants: n ϭ 6 each for hE1-2, n ϭ 9 each for hMOR-1S, and n ϭ 6 each for hMOR-1Z). *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001. Figure 7 . Effect of an antisense vivo-morpholino oligo targeting the G-rich region containing rs9479757 on exon 2 inclusion/skipping and hMOR-1 protein expression. A, Effect of the antisense vivo-morpholino oligo on exon 2 inclusion/skipping by regular RT-PCR. RNA extracted from Be(2)C cells treated with 1 M antisense vivo-morpholino oligo (Ant) or control morpholino oligo (Ctr) alone, or combined with BAC minigene construct G31 (hBAC-G31) were used in regular RT-PCR with SP-1 and AP-1 primers for the variants and G3PDH primers. Bands for hMOR-1, hMOR-1Z, and hMOR-1S are shown by boxes labeled as 1/2/3/4, 1/3/4, and 1/4, respectively. B, C, Effect of the antisense vivo-morpholino oligo on endogenous exon 2 inclusion/skipping (B) or exogenous (hBAC-G31) exon 2 inclusion/skipping (C) by qRT-PCR. The same cDNAs in A were used in SYBR green qPCR, as described in Materials and Methods. hE1-2 mainly represents hMOR-1. The fold change was calculated through the 2 Ϫ⌬⌬C(t) format, where the ⌬⌬C(t) value was the difference in ⌬C(t) values between the Ant and the Ctr samples so that the (Figure legend continues.) the homozygous AA genotype through the hnRNPH siRNA treatment, and that hnRNPH positively regulates exon 2 inclusion via the G triplets in intron 2.
An antisense morpholino oligo targeting rs9479757 increases exon 2 skipping Antisense morpholino oligos are commonly used to modulate alternative splicing since they do not trigger RNase H-mediated degradation. To investigate the effect of blocking hnRNPH binding and other associated splicing factors to the SNP-contained region on exon 2 splicing, we designed an antisense morpholino oligo targeting the region (Fig. 5A) . When introduced into Be(2)C cells, the antisense oligo significantly increased expression of both the endogenous and exogenous (transfected hBAC-G31) hMOR-1S (for endogenous hMOR-1S: t (16) ϭ 2.69, p Ͻ 0.05; for exogenous hMOR-1S: t (14) ϭ 3.11, p Ͻ 0.01) and hMOR-1Z mRNA (for endogenous hMOR-1Z: t (16) ϭ 3.02, p Ͻ 0.01; for exogenous hMOR-1Z: t (14) ϭ 2.96, p Ͻ 0.05), and reduced the expression of hE1-2 mRNA (for endogenous hE1-2: t (16) ϭ 2.61, p Ͻ 0.05; for exogenous hE1-2: t (14) ϭ 2.45, p Ͻ 0.05; Fig. 7A-C) . These findings are similar to those from the hnRNPH siRNA studies (Fig.  6) , suggesting that the antisense morpholino oligo facilitated exon 2 skipping by presumably blocking hnRNPH binding. Again, the splicing change in the Be(2)C cells with the AG genotype by the antisense morpholino oligo treatment mimicked that seen in the transfected BAC minigene constructs with the homozygous AA genotype. To examine whether or not there is a parallel change in hMOR-1 protein expression by the antisense morpholino oligo treatment, we performed Western blots using an hMOR-1 exon 4 antibody. We were unable to determine the expression levels of hMOR-1S and hMOR-1Z proteins due to a lack of specific antibodies. However, we observed that the antisense morpholino oligo treatment significantly increased the expression of hMOR-1 protein (t (6) ϭ 2.63; p Ͻ 0.05; Fig. 7 D, E) , contradicting its effect on hMOR-1 mRNA expression (Fig. 7A-C Fig. 7 F, G) . Since single TM variants alone do not bind any opioids, the increased [ were indeed contributed by the increased hMOR-1 protein expression. Our previous studies using a Tet-Off CHO cell model indicate that single TM variants such as mMOR-1S can dimerize with the full-length 7-TM mMOR-1 in the endoplasmic reticulum (ER), leading to increased protein expression of mMOR-1 by a chaperone-like function that minimizes ER-associated degradation . In vivo administration of an antisense oligo targeting mMOR-1S significantly reduced expressions of mMOR-1 proteins in the spinal cord and periaqueductal gray with no effect on the expression of mMOR-1 mRNA, and consequently decreased morphine analgesia . Therefore, it is likely that the increase in hMOR-1 protein expression observed in the antisense morpholino oligo study can be explained by an increase in expression of the single TM variants hMOR-1S and hMOR-1Z, with similar mechanisms seen in the Tet-Off cells and mice. Notably, the effect of the antisense morpholino oligo on hMOR-1 protein expression was stronger than its effect on hMOR-1 mRNA expression.
rs9479757 genotypes are associated with differential mRNA expression of the OPRM1 splice variants and hMOR-1 protein in human postmortem prefrontal cortex We next investigated whether or not the results from our in vitro and cell culture studies could be recapitulated in human postmortem brain samples. Using qRT-PCR, we analyzed the expression of the OPRM1 variant mRNAs in 19 PFC samples with the GG genotype (15 samples) and the AG genotype (12 samples). No samples with AA genotype were available for postmortem analysis. We observed that the subjects with the AG genotype expressed significantly higher levels of hMOR-1S (t (25) ϭ 3.39; p Ͻ 0.01) and hMOR-1Z (t (25) ϭ 2.58; p Ͻ 0.05) in the PFC, and lower levels of hE1-2 (mainly representing hMOR-1; t (25) ϭ 3.08; p Ͻ 0.01), compared with individuals with the GG genotype (Fig.  8A) . Next, we used Western blots to examine the expression of the hMOR-1 protein in these PFC samples. The samples with the AG genotype expressed significantly higher hMOR-1 protein than the samples with the GG genotype (t (13) ϭ 2.29; p Ͻ 0.05; Fig. 8 B, C) . These results were very similar to those observed in the Be(2)C cells treated with the antisense morpholino oligo, suggesting that in the human PFC the AG genotype favors exon 2 skipping to increase single TM variant mRNA and reduce hMOR-1 mRNA expression, whereas the GG genotype favors opposite changes. The increased hMOR-1 protein expression in the samples with the AG genotype is also due to the increased single TM variants from the increased exon 2 skipping. rs9479757 is associated with different sets of RNA processing proteins through hnRNPH To further explore the roles of rs9479757 in OPRM1 alternative splicing, we used an RNA affinity purification coupled with the LC-MS/MS approach to investigate how this polymorphism influences its association with splicing factors or trans-acting factors through hnRNPH. The same biotinylated RNA bait oligo containing a G or an A allele used in the UV cross-linking studies (see above) was used for purifying its associated proteins with nuclear extract from Be(2)C cells. We adapted an RNA purification strategy using monomeric avidin resin that allows gentle elution with biotin solution, thus reducing nonspecific elution. Analyzing the data from LC-MS/MS revealed that 128 nuclear proteins were associated with the G31 oligo, and 41 nuclear proteins were associated with the A31 oligo (Table 6 ; Fig. 9A ). Of those identified proteins, 28 proteins were associated with both 4 (Figure legend continued. ) expression level in the Ctr samples is always 1. Bars represent the mean Ϯ SEM. Student's t test was used (n ϭ 9 each for endogenous variants; n ϭ 8 each for exogenous variants). *p Ͻ 0.05; **p Ͻ 0.01. D, Western blot analysis. Proteins from Be(2)C cells treated with the Ctr or the Ant oligo were used for Western blot analysis with a hMOR-1 antibody or a GAPDH antibody. E, Quantification of Western blots. Band intensities of hMOR-1 were adjusted with those of GAPDH. Expression level of hMOR-1 in the Ant samples was normalized with that in the Ctr samples, so that the Ctr is 100%. Bars represent the mean Ϯ SEM. Student's t test was used (n ϭ 4 each). *p Ͻ 0.05. splicing. Together, these findings provide a reasonable rationale for how the G-to-A transition led to reduced exon 2 inclusion or intron 2 excision. We also observed that among 128 proteins associated with the G31 oligo, 45 proteins are known to relate to transcription and 20 proteins have chromatin binding abilities ( Fig. 9A ; Table 6 ). Some of these proteins have overlapping roles in transcription, chromatin binding, and splicing. Again, fewer proteins associated with the A31 oligo relate to transcription (17 proteins) and chromatin binding (5 proteins; Fig. 9 ; Table 6 ). These findings not only support the notion that alternative splicing is tightly coupled with transcription and chromatin remodeling, but also provide new clues to how hnRNPH-mediated alternative splicing is coupled to transcription and chromatin remodeling.
Discussion
The current study describes a significant association of an intronic SNP, rs9479757, with the severity of heroin addiction in HanChinese male heroin addicts. Heroin addicts with the AG genotype were more inclined to mild heroin addiction in contrast to heroin addicts with the GG genotype, who were predisposed to severe heroin addiction. This hypothesis was supported by individual SNP analysis and haplotype-based analysis with additional SNPs in the OPRM1 locus. Importantly, significant associations with four SNPs within the same haplotype block strongly illustrate the influence of genetic variation on the severity of heroin addiction. Conditional haplotype analysis demonstrates that the genetic signal at this locus is fully explained, at least for the SNPs tested, by rs9479757. One theoretical factor influencing our association study is population stratification among the Chinese population. Though this is often a concern in studies conducted in the heterogeneous population of the United States, and adjusted for using ancestry-informative markers, this is less of a concern in this Chinese population as all participants in our study are Han-Chinese recruited from Ningbo City where there is limited population migration. Shi et al. (2002) previously reported that the heroin addicts with the rs9479757 GG genotype in a mixed male and female population were likely to consume a small daily dose of heroin. However, they also showed that the heroin addicts with both the rs9479757 GG and the rs1799971 AG/GG genotypes had a greater daily heroin intake. It is difficult to make a comparison between the study of Shi et al. (2002) and our study because the gender, sample size, and criteria for the severity of heroin addiction in our study were different. We realize that the sample size in our study is relatively small, and it needs to be replicated in a second cohort or larger sample size. Nevertheless, our data suggest that genetic variants of the OPRM1 gene can be used for predicting the severity of heroin addiction.
Our EMAS and UV cross-linking studies have established that hnRNPH is the major binding partner for the SNP G-containing site, and the G-to-A transition of this site significantly lowered the binding affinity for hnRNPH, suggesting that during splicing, pre-mRNA with the G allele attracts more hnRNPH proteins to the 5Ј splice site of intron 2 than pre-mRNA with the A allele, thus modulating exon 2 splicing. This suggestion was validated by our studies using BAC minigene constructs in Be(2)C cells. Our results showed that the G allele of rs9479757 facilitated exon 2 inclusion to decrease the expression of hMOR-1S and hMOR-1Z, and to increase the expression of hMOR-1 mRNA. In contrast, the A allele reduced exon 2 inclusion with opposite effects on mRNA expression of the splice variants. These results were further supported by evidence of splicing changes in the human postmortem PFC with either the AG or GG genotype. Together, these findings demonstrate that the G-contained SNP site functions as an ISE, and that the binding of hnRNPH to this ISE enhances exon 2 inclusion. The G-to-A transition weakens the ISE by decreasing hnRNPH binding, thus leading to the reduction of exon 2 inclusion.
Involvement of hnRNPH in exon 2 inclusion/skipping was further supported by our siRNA studies. Downregulating the expression of hnRNPH by siRNAs led to the reduction of exon 2 inclusion in both the endogenous OPRM1 gene and the exogenously transfected BAC minigene, a scenario similar to that seen in the G-to-A transition of the SNP. Furthermore, blocking the SNP-contained ISE site to which hnRNPH binds with an antisense vivo-morpholino oligo effectively weakened exon 2 inclusion, not only supporting the role of the ISE site and hnRNPH in exon 2 inclusion/skipping, but also providing potential tools to modulate exon 2 inclusion/skipping and the expression of the full-length MOR-1 and single TM variants in vivo.
G-rich regions or repeats have long been known to frequently be present at 5Ј introns (Engelbrecht et al., 1992) and involve in exon inclusion and intron excision, acting mainly as an ISE. These G-rich ISE regions have been found in chicken ␤-tropomycin (Sirand-Pugnet et al., 1995) , cardiac troponin T genes (Carlo et al., 1996) , minute virus of mice (Haut and Pintel, 1998), human ␣-globin (McCullough and Berget, 1997) , and growth hormone genes (McCarthy and Phillips, 1998) . Our results provide another example of how G triplets can promote exon inclusion. U1 snRNPs and hnRNP proteins, especially hnRNPH, have been implicated in mediating the activity of G-rich ISE (Wang and Cambi, 2009) .
Despite reduced hMOR-1 mRNA expression, it is intriguing to observe an increase in the levels of hMOR-1 protein in Be(2)C cells treated with the antisense morpholino oligo, as well as in the postmortem PFC samples with the AG genotype. Importantly, along with the above findings, the altered splicing in both these samples showed an increase in the expression of single TM variants hMOR-1S and hMOR-1Z, which have previously been dem- 
Total spectrum (Spe) count was from analysis of LC-MS/MS data using Scaffold software. Related functions including splicing, transcription, chromatin (Chr) binding, and RNA binding for the listed proteins were obtained from analysis using Ingenuity Serve. G31 and A31, Biotinylated RNA oligos used in RNA affinity purification. Figure 9 . Schematic of proteins identified by RNA affinity purification-coupled LC-MS/MS and the hnRNPH-associated protein network recruited by the G-containing SNP site. A, Schematic of proteins identified by the G31 and A31 oligos. Top, Red and green circles represent proteins identified from the G31 and A31 oligos, respectively. Bottom, Three colored circles indicate proteins that have indicated functions by colored arrows from the G31 oligo (right) or from the A31 oligo (left). Overlapping area shows shared proteins. The number of unique and shared proteins is indicated within the circle and overlapping areas. B, Schematic of hnRNPH-associated protein network recruited by the G-containing SNP site. Protein-protein interactions among the purified proteins with the G31 oligo were obtained using Ingenuity systems. Selected proteins were drawn. Red bar represents G-rich ISE containing rs9479757 SNP. hnRNP proteins and SRSF proteins are shown by oval shapes with light brown and blue colors, respectively. The yellow diamond shape is RBM25, which is associated with U1 snRNP. Light green shapes are proteins linked to U2 snRNP. Light purple shapes are linked to U4/U6 or U5 snRNP. Light red and dark yellow shapes are proteins related to transcription and chromatin binding, respectively.
onstrated to increase the expression of the functional full-length 7-TM MOR-1 at the protein level in both in vitro cell models and in vivo mouse models, as well as enhancing morphine analgesia, through a chaperon-like action. The single TM variants have also been implicated in disrupting heterodimerization of MOR-1 and DOR-1 to reduce MOR-1 protein degradation (He et al., 2011) . Therefore, we speculate that the increase in single TM variants accounts for the observed increase in levels of hMOR-1 protein in these current studies. However, other mechanisms such as translation regulation cannot be ruled out. Previous reports showed that expression levels of MOR-1 protein can be regulated by a nonsynonymous SNP, rs1799971 (A118G), that either altered the secondary mRNA structure to influence MOR-1 translation or modified the N-glycosylation of the receptor to affect MOR-1 protein stability (Huang et al., 2012) . Our results endorse a new case that the expression level of MOR-1 protein can be modulated by an intronic SNP that acts as a splicing modifier via hnRNPH interactions, providing an important functional link between the regulation of hMOR-1 protein expression and the severity of heroin addiction. Huang et al. (2008) reported that healthy Han-Chinese women with the AG genotype of this SNP had significantly higher pressure pain threshold (PPT) than those with the GG genotype. One potential explanation for the higher PPT seen in women with the AG genotype is that, similar to the heroin addicts, the women with the AG genotype express more hMOR-1 protein, presumably due to the role of increased levels of single TM variants. Though this interpretation is speculative, the data somewhat support our finding that the genotype of this SNP is associated with the expression level of hMOR-1 protein in heroin addicts.
hnRNPH was originally identified as an RNA binding protein with three quasi-RNA recognition motifs that bind to a G-rich sequence (Honoré et al., 1995) . hnRNPH involves a wide range of mRNA processing and has diverse roles in exon or intron definition. When bound to exons, hnRNPH typically inhibits exon inclusion by antagonizing enhancers or spliceosome components (Chen et al., 1999; Mauger et al., 2008; Lefave et al., 2011) . When bound to introns, hnRNPH promotes exon inclusion, as initially demonstrated in regulating the c-src N1 exon inclusion via interaction with the G-rich ISE (Chou et al., 1999) . Mechanistically, it has been proposed that hnRNPH interacts with hnRNP A/B in intronic G-rich regions to loop out intronic regions (MartinezContreras et al., 2006) or to recruit U1 snRNP (Wang and Cambi, 2009 ). Here, we show an additional example of hnRNPHmediated exon inclusion in the OPRM1 gene, which uses a G-rich 5Ј intron 2 region containing a heroin addiction severityassociated SNP. Our data from RNA affinity purificationcoupled LC-MS/MS demonstrate that the hnRNPH-mediated splicing regulation in the OPRM1 gene involves multiple hnRNPH-associated proteins. In this context, our data show that hnRNPH has the capacity to organize a large protein complex or network that contributes significantly to splicing and transcription, and that an intronic SNP can modulate the formation and function of this hnRNPH-mediated protein complex.
Although our data suggest that an intronic SNP influences OPRM1 alternative splicing and can predict the severity of heroin addiction, the exact pathways linking SNP-mediated changes in OPRM1 alternative splicing, the expression of MOR-1 and single TM variants to the phenotypic severity of heroin addiction remain unknown. Further delineating the mechanisms behind this association using various approaches such as in vivo brain imaging with appropriate agonist markers and gene targeting mouse models mimicking the human genotypes will greatly advance our understanding of the genetic influence on the severity of heroin addiction.
In conclusion, our current studies illustrate the association of an intronic SNP (rs9479757) with heroin addiction severity among Chinese male heroin addicts. Furthermore, we establish the functional relevance of this SNP in modulating OPRM1 alternative splicing through hnRNPH-mediated splicing regulation and expression of hMOR-1 protein. Our findings provide new insights into the role of this intronic SNP on heroin addiction severity and OPRM1 alternative splicing. We suggest a functional link between an SNP-containing splicing modifier and heroin addiction severity, via hnRNPH interactions.
